C4 Therapeutics, Inc. Sample Contracts

C4 Therapeutics, Inc. UNDERWRITING AGREEMENT
Underwriting Agreement • June 14th, 2021 • C4 Therapeutics, Inc. • Biological products, (no disgnostic substances) • New York
Sample 1Sample 2Sample 3See All (680)
AutoNDA by SimpleDocs
C4 THERAPEUTICS, INC. SHARES OF COMMON STOCK SALES AGREEMENT
Sales Agreement • November 10th, 2021 • C4 Therapeutics, Inc. • Biological products, (no disgnostic substances) • New York

C4 Therapeutics, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with Cowen and Company, LLC (“Cowen”), as follows:

Sample 1Sample 2Sample 3See All (275)
EMPLOYMENT AGREEMENT
Employment Agreement • September 10th, 2020 • C4 Therapeutics, Inc. • Biological products, (no disgnostic substances) • Massachusetts

This Employment Agreement (“Agreement”) is made by and between C4 Therapeutics (the “Company”), and (the “Executive”), and is effective as of this __ day of __________, 20__ (the “Effective Date”).

Sample 1Sample 2Sample 3See All (117)
C4 THERAPEUTICS, INC. [FORM OF] DIRECTOR INDEMNIFICATION AGREEMENT
Director Indemnification Agreement • September 10th, 2020 • C4 Therapeutics, Inc. • Biological products, (no disgnostic substances) • Delaware

This Indemnification Agreement (“Agreement”) is made as of [Date] by and between C4 Therapeutics, Inc., a Delaware corporation (the “Company”), and [Director Name] (“Indemnitee”).

Sample 1Sample 2Sample 3See All (90)
C4 THERAPEUTICS, INC. [FORM OF] OFFICER INDEMNIFICATION AGREEMENT
Officer Indemnification Agreement • September 10th, 2020 • C4 Therapeutics, Inc. • Biological products, (no disgnostic substances) • Delaware

This Indemnification Agreement (“Agreement”) is made as of [Date] by and between C4 Therapeutics, Inc., a Delaware corporation (the “Company”), and [Officer Name] (“Indemnitee”). 1

Sample 1Sample 2Sample 3See All (58)
LEASE BY 480 ARSENAL GROUP LLC, LANDLORD TO C4 THERAPEUTICS, INC., TENANT LINX Building 490 Arsenal Way Watertown, Massachusetts 02472
Lease • September 10th, 2020 • C4 Therapeutics, Inc. • Biological products, (no disgnostic substances) • Massachusetts
Sample 1Sample 2
COLLABORATION AND LICENSE AGREEMENT
Collaboration and License Agreement • September 10th, 2020 • C4 Therapeutics, Inc. • Biological products, (no disgnostic substances) • New York

This Collaboration and License Agreement (“Agreement”) is entered into with effect as of March 13, 2017 (the “Effective Date”) by and between C4 Therapeutics, Inc. with an office and place of business at 675 W. Kendall St., Cambridge, MA 02142 (“C4T”) and Calico Life Sciences LLC with an office and place of business at 1170 Veterans Blvd, South San Francisco, CA 94080 (“Calico”) (a “Party” or together, “Parties”).

Sample 1Sample 2
Amended and Restated License Agreement
License Agreement • September 10th, 2020 • C4 Therapeutics, Inc. • Biological products, (no disgnostic substances) • New York

with an office and place of business at 150 Clove Road, Suite 8, Little Falls, New Jersey 07424, U.S.A. (“Roche US”; Roche Basel and Roche US together referred to as “Roche”)

Sample 1Sample 2
COLLABORATIVE RESEARCH AND LICENSE AGREEMENT BETWEEN BIOGEN MA INC. AND C4 THERAPEUTICS, INC. Dated December 28, 2018
Collaborative Research and License Agreement • September 10th, 2020 • C4 Therapeutics, Inc. • Biological products, (no disgnostic substances) • New York

This COLLABORATIVE RESEARCH AND LICENSE AGREEMENT (this “Agreement”) is entered into as of December 28, 2018 (the “Effective Date”) by and among Biogen MA Inc., a corporation organized and existing under the laws of Massachusetts and having a principal place of business at 225 Binney Street, Cambridge, MA 02142 (“Biogen”) and C4 Therapeutics, Inc., a corporation organized and existing under the laws of Delaware with a principle place of business at 490 Arsenal Way, Watertown, MA 02472 (“C4”). Biogen and C4 are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”

Sample 1Sample 2
CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED AND REPLACED WITH “[***]”. SUCH IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF...
Credit Agreement • September 10th, 2020 • C4 Therapeutics, Inc. • Biological products, (no disgnostic substances) • New York

CREDIT AGREEMENT AND GUARANTY, dated as of June 5, 2020 (this “Agreement”), among C4 THERAPEUTICS, INC., a Delaware corporation (the “Borrower”), certain Guarantors from time to time parties hereto, PERCEPTIVE CREDIT HOLDINGS III, LP, a Delaware limited partnership (“Perceptive”), as a lender (together with its successors and assigns party hereto pursuant to Section 13.05, the “Lenders” and each a “Lender”) and as administrative agent for the Lenders (in such capacity, together with its successors and assigns, the “Administrative Agent”).

Sample 1Sample 2
AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT
Investors’ Rights Agreement • September 10th, 2020 • C4 Therapeutics, Inc. • Biological products, (no disgnostic substances) • Delaware

THIS AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT (this “Agreement”), is made as of June 5, 2020, by and among C4 Therapeutics, Inc., a Delaware corporation (the “Company”), and each of the investors listed on Schedule A hereto, each of which is referred to in this Agreement as an “Investor”, the stockholders set forth on Schedule B hereto as the “Key Holders”, and any additional purchaser that becomes a party to this Agreement in accordance with Section 6.9 hereof (collectively, the “Additional Purchasers”).

Sample 1
STOCK PURCHASE AGREEMENT between C4 Therapeutics, Inc., Betta Investment (Hong Kong) Limited and Betta Pharmaceuticals Co., Ltd. Dated as of May 29, 2023
Stock Purchase Agreement • May 30th, 2023 • C4 Therapeutics, Inc. • Biological products, (no disgnostic substances) • New York

This Stock Purchase Agreement (this “Agreement”) is made as of May 29, 2023, by and among C4 Therapeutics, Inc., a Delaware corporation (the “Company”), Betta Investment (Hong Kong) Limited, a limited liability company established under the laws of Hong Kong (the “Investor”), and Betta Pharmaceuticals Co., Ltd., a limited liability company established under the laws of PRC and the sole stockholder of the Investor (the “Parent”).

Sample 1
Certain information in this document has been omitted from this exhibit because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed. AMENDMENT NO. 1 TO COLLABORATIVE RESEARCH AND LICENSE AGREEMENT
Collaborative Research and License Agreement • March 11th, 2021 • C4 Therapeutics, Inc. • Biological products, (no disgnostic substances)

THIS AMENDMENT NO. 1 TO COLLABORATIVE RESEARCH AND LICENSE AGREEMENT ("Amendment") is made as of February 25, 2020, by and among C4 Therapeutics, Inc., a Delaware corporation ("C4") and Biogen MA Inc., a Massachusetts corporation ("Biogen").

Sample 1
ACTIVE/128326788.11 Confidential Execution Copy Certain identified information has been excluded from this exhibit because it is both not material and is the type that the registrant treats as private or confidential. Information that was omitted has...
Research Collaboration and License Agreement • May 8th, 2024 • C4 Therapeutics, Inc. • Biological products, (no disgnostic substances) • Delaware
Sample 1
First Amendment To Amended and Restated license Agreement
License Agreement • March 11th, 2021 • C4 Therapeutics, Inc. • Biological products, (no disgnostic substances) • England

This First Amendment (the “First Amendment”), effective as of November 12, 2020 (“Amendment Effective Date”) is an amendment to that certain Amended and Restated License Agreement by and between F. Hoffmann-La Roche Ltd, with an office and place of business at Grenzacherstrasse 124, 4070 Basel, Switzerland (“Roche Basel”) and Hoffmann-La Roche Inc., with an office and place of business at 150 Clove Road, Suite 8, Little Falls, NJ 07424 USA (“Roche US” and, collectively with Roche Basel, “Roche”), on the one hand, and C4 Therapeutics, Inc., with an office and place of business at 490 Arsenal Way, Suite 200, Watertown, MA 02472 (“C4T”) (the “Restated Agreement”). Capitalized terms that are not defined herein shall have the meaning ascribed to them in the Restated Agreement.

Sample 1
THIRD AMENDMENT TO LEASE
Lease • November 30th, 2021 • C4 Therapeutics, Inc. • Biological products, (no disgnostic substances)

This THIRD AMENDMENT TO LEASE (this “Third Amendment”) is made and entered into as of November 24, 2021 (the “Effective Date”), by and between COLUMBIA MASSACHUSETTS ARSENAL OFFICE PROPERTIES, LLC, a Delaware limited liability company (“Landlord”) and C4 THERAPEUTICS, INC., a Delaware corporation (“Tenant”), who both mutually acknowledge and concur, as follows:

Sample 1
LICENSE AND COLLABORATION AGREEMENT By and Between C4 THERAPEUTICS, INC., and BETTA PHARMACEUTICALS CO., LTD. May 29, 2023
License and Collaboration Agreement • May 30th, 2023 • C4 Therapeutics, Inc. • Biological products, (no disgnostic substances)

This License and Collaboration Agreement (the “Agreement”) is entered into as of May 29, 2023 (the “Effective Date”), by and between C4 Therapeutics, Inc., a corporation having a place of business at 490 Arsenal Way, Suite 120, Watertown, MA 02472, the United States (“C4T”), and Betta Pharmaceuticals Co., Ltd., a company having a place of business at 355 Xingzhong Road, Linping District, Hangzhou, Zhejiang, P.R. China 311100 (“Licensee”).

Sample 1
ACTIVE/104115192.2 C4 THERAPEUTICS, INC. NON-QUALIFIED STOCK OPTION AGREEMENT (INDUCEMENT GRANT) Name of Optionee: No. of Option Shares: Option Exercise Price per Share: $ [FMV on Grant Date] Grant Date: Expiration Date: C4 Therapeutics, Inc. (the...
Non-Qualified Stock Option Agreement • February 22nd, 2024 • C4 Therapeutics, Inc. • Biological products, (no disgnostic substances)
Sample 1
C4 THERAPEUTICS, INC. CONSULTATION AGREEMENT
Consultation Agreement • September 10th, 2020 • C4 Therapeutics, Inc. • Biological products, (no disgnostic substances) • Massachusetts

Consultation Agreement (“Agreement”), effective as of March 31, 2020 (the “Effective Date”), between C4 Therapeutics, Inc., a Delaware corporation, having a place of business at 490 Arsenal Way, Suite 200, Watertown, MA 02472 (“C4T” or “Company”), and MBJC Associates, LLC having an address at 832 Schirra Drive, Oradell, New Jersey 07649 (“Consultant”).

Sample 1
2 - ACTIVE/132189260.2 ACTIVE/132189260.4 to the Placement Shares. Except where the context otherwise requires, such registration statement, and any post- effective amendment thereto, as amended when it becomes effective, including all documents filed...
Shares of Common Stock Sales Agreement • October 31st, 2024 • C4 Therapeutics, Inc. • Biological products, (no disgnostic substances) • New York
Sample 1
EXECUTION VERSION Certain identified information has been excluded from this exhibit because it is both not material and is the type that the registrant treats as private or confidential. Information that was omitted has been noted in this document...
License and Collaboration Agreement • February 22nd, 2024 • C4 Therapeutics, Inc. • Biological products, (no disgnostic substances) • New York
Sample 1
Draft better contracts in just 5 minutes Get the weekly Law Insider newsletter packed with expert videos, webinars, ebooks, and more!